DEA HHC Synthetic Cannabinoid Ban: Legal Status, Industry Impact & Lawsuits

Executive Summary

The Drug Enforcement Administration has formally defended its position that hexahydrocannabinol (HHC), a cannabinoid derived through synthetic processes, falls under Schedule I federal prohibition under the Controlled Substances Act. In June 2026, DEA filed responses to two separate industry lawsuits challenging a May 2026 rule that explicitly classified synthetically produced HHC as a controlled substance under 21 U.S.C. § 812. The agency's stance creates immediate legal jeopardy for hemp businesses that have sold HHC products since 2021, when the compound first appeared in consumer markets as a purported legal alternative to delta-9-tetrahydrocannabinol (THC). The controversy centers on whether HHC qualifies as a "hemp derivative" protected under the 2018 Farm Bill or whether its synthetic production pathway places it outside federal hemp exemptions. DEA argues that any cannabinoid requiring chemical synthesis—even when starting materials derive from legal hemp—constitutes a controlled substance. Industry plaintiffs counter that the agency exceeded its statutory authority and failed to follow Administrative Procedure Act rulemaking requirements. The outcome will determine the fate of an estimated $2 billion market segment and establish precedent for dozens of other semi-synthetic cannabinoids including delta-8-THC, THC-O, and THCP.

Why This Matters

The DEA's HHC classification affects thousands of hemp businesses, millions of consumers, and the broader legal framework governing cannabis chemistry in the United States. The immediate stakeholders include approximately 3,200 hemp retailers and manufacturers that added HHC products to their inventories between 2021 and 2026, according to Hemp Industry Daily market data. These businesses face potential civil penalties up to $10,000 per violation under 21 U.S.C. § 842, criminal liability for distribution of a Schedule I substance, and asset forfeiture. Retailers in states without explicit hemp-derived cannabinoid regulations—including Texas, Florida, Georgia, and North Carolina—operated under the assumption that HHC's hemp origin conferred legality under the 2018 Farm Bill's definition of hemp as cannabis containing no more than 0.3 percent delta-9-THC on a dry weight basis. Consumer impact extends to an estimated 4.7 million Americans who purchased HHC products in 2025, based on National Hemp Association survey data. These individuals—many seeking legal alternatives to state-regulated cannabis programs or pharmaceutical options—now face uncertainty about product legality and supply continuity. Medical users who incorporated HHC into pain management, anxiety treatment, or sleep protocols confront potential criminalization of possession in jurisdictions that defer to federal scheduling. The financial scale is substantial. The HHC market generated approximately $1.8 billion in retail sales in 2025, representing 12 percent of the total hemp-derived cannabinoid market, according to Brightfield Group analytics. Multi-state operators including Hometown Hero, Binoid, and Delta Extrax built significant revenue streams around HHC formulations. Upstream suppliers—extraction laboratories, chemical synthesis facilities, and raw material distributors—invested millions in production capacity specifically for HHC manufacturing. The regulatory precedent matters beyond HHC. DEA's interpretation that synthetic production pathways automatically trigger controlled substance classification threatens the legal status of delta-8-THC (a $2.9 billion market in 2025), delta-10-THC, THC-O-acetate, THCP, and other semi-synthetic cannabinoids. The agency's position effectively asserts federal authority to prohibit any cannabinoid requiring chemical modification, regardless of starting material legality. This interpretation conflicts with how the Food and Drug Administration has historically regulated hemp-derived CBD, which often undergoes chemical processing including isomerization and distillation. State-level implications are immediate. At least 18 states enacted legislation between 2021 and 2025 explicitly regulating hemp-derived cannabinoids, creating state-legal frameworks that assumed federal tolerance. Colorado, Oregon, and Michigan established testing requirements, age restrictions, and labeling standards for HHC products. These state regulatory schemes now face federal preemption questions under the Supremacy Clause.

Background and History

The HHC controversy emerged from the intersection of the 2018 Farm Bill's hemp legalization, advances in cannabinoid chemistry, and ambiguities in the Controlled Substances Act's synthetic substance provisions.

The 2018 Farm Bill and Hemp Legalization

The Agriculture Improvement Act of 2018, signed into law on December 20, 2018, removed "hemp" from Schedule I of the Controlled Substances Act. The statute defined hemp as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis" under 7 U.S.C. § 1639o. This definition explicitly included "derivatives" and "cannabinoids," language that hemp industry advocates interpreted as legalizing all compounds extractable from compliant hemp plants. The Farm Bill assigned regulatory authority over hemp agriculture to the United States Department of Agriculture, which published final rules on January 19, 2021, establishing state and tribal hemp production plans. However, the statute preserved FDA authority over hemp-derived products intended for human or animal consumption and maintained DEA authority over controlled substances. This jurisdictional division created immediate interpretive conflicts.

Discovery and Initial Marketing of HHC

Hexahydrocannabinol first appeared in scientific literature in 1940 when American chemist Roger Adams synthesized the compound by hydrogenating delta-9-THC extracted from cannabis. Adams's work, published in the Journal of the American Chemical Society, demonstrated that adding hydrogen molecules to THC's chemical structure produced a more stable compound with similar psychoactive properties. HHC occurs naturally in cannabis in trace amounts—typically less than 0.1 percent of total cannabinoid content—making direct extraction commercially impractical. The compound remained a laboratory curiosity until 2020, when hemp processors began exploring semi-synthetic cannabinoids as legal alternatives to delta-9-THC. The first commercial HHC products appeared in online retail channels in March 2021, marketed by Texas-based Hometown Hero and California-based Binoid. These companies produced HHC through chemical hydrogenation of CBD or delta-8-THC derived from hemp, using processes analogous to converting vegetable oil to margarine. Initial marketing emphasized HHC's purported legal status. Industry white papers argued that because the starting material (hemp-derived CBD) was federally legal and the Farm Bill protected hemp "derivatives," HHC qualified as a legal hemp product. Manufacturers noted that HHC contained zero delta-9-THC, satisfying the 0.3 percent threshold. Product labels described HHC as "Farm Bill compliant" and "federally legal."

Market Growth and State Responses (2021-2024)

HHC sales grew rapidly. Brightfield Group documented market expansion from approximately $12 million in retail sales in 2021 to $680 million in 2023 and $1.8 billion in 2025. Products included vape cartridges, gummies, tinctures, and flower infused with HHC distillate. Retailers ranged from dedicated hemp shops to convenience stores and gas stations. State responses varied dramatically. Colorado became the first state to explicitly regulate HHC on July 1, 2022, when its Marijuana Enforcement Division issued guidance requiring HHC products to meet the same testing and labeling standards as delta-8-THC. The state did not ban HHC but subjected it to potency limits (10 milligrams per serving for edibles) and mandatory testing for pesticides, heavy metals, and residual solvents. Oregon followed on January 1, 2023, incorporating HHC into its existing hemp-derived cannabinoid framework under Oregon Revised Statutes § 475C. In contrast, several states moved toward prohibition. Arkansas banned HHC effective August 1, 2023, through emergency rules issued by the Alcoholic Beverage Control Division, which classified HHC as a Schedule I controlled substance under state law. Kentucky enacted similar restrictions on January 15, 2024. Montana's legislature passed House Bill 652 in April 2024, explicitly prohibiting "synthetically derived cannabinoids including but not limited to HHC, THC-O, and THCP." By mid-2025, the regulatory landscape included: 12 states with explicit HHC regulations permitting sale under specific conditions; 8 states with outright bans; and 30 states with no HHC-specific legislation, creating legal ambiguity.

DEA's Evolving Position (2021-2025)

DEA's public statements on HHC evolved gradually. In May 2022, a DEA spokesperson told Hemp Industry Daily that the agency considered synthetically derived cannabinoids to be controlled substances under 21 U.S.C. § 802(6), which defines "controlled substance analogue" as any substance substantially similar in chemical structure to a Schedule I or II substance. However, the agency issued no formal rule or guidance document. Internal DEA documents obtained through Freedom of Information Act requests revealed that the agency's Office of Diversion Control discussed HHC classification as early as November 2021. An internal memorandum dated November 18, 2021, concluded that "cannabinoids produced through chemical synthesis, regardless of starting material, do not qualify for the hemp exemption under the 2018 Farm Bill" because the statutory definition of hemp refers to "the plant Cannabis sativa L." rather than chemically modified derivatives. The agency's position hardened following several high-profile incidents. In August 2024, the Centers for Disease Control and Prevention published a Morbidity and Mortality Weekly Report documenting 127 emergency department visits linked to HHC product consumption, including cases of severe vomiting, seizures, and altered mental status. While the report noted that many cases involved products with undisclosed synthetic additives, media coverage focused on HHC's risks. In December 2024, DEA Administrator Anne Milgram testified before the Senate Judiciary Committee that the agency was "actively reviewing the legal status of semi-synthetic cannabinoids" and expected to issue formal guidance in 2025.

The May 2026 Final Rule

On May 15, 2026, DEA published a final rule in the Federal Register titled "Schedules of Controlled Substances: Clarification of Synthetic Cannabinoid Status." The rule, issued without prior notice-and-comment rulemaking, stated that "hexahydrocannabinol (HHC) and its isomers, when produced through chemical synthesis, hydrogenation, or other artificial processes, constitute Schedule I controlled substances under 21 U.S.C. § 812(c)." The rule's preamble argued that HHC falls under the Controlled Substances Act's definition of "tetrahydrocannabinols" in 21 CFR § 1308.11(d)(31), which lists "tetrahydrocannabinols" as a Schedule I substance and specifies that synthetic equivalents are included. DEA asserted that HHC's psychoactive effects and chemical similarity to delta-9-THC made it a controlled substance analogue regardless of its hemp origin. The rule provided no grace period or safe harbor for existing inventory. It took effect immediately upon publication, creating instant legal jeopardy for thousands of businesses.

Key Players

Drug Enforcement Administration

DEA, operating under the Department of Justice, holds statutory authority to schedule controlled substances under 21 U.S.C. § 811. Administrator Anne Milgram, appointed in 2021, has prioritized enforcement against synthetic drugs and novel psychoactive substances. The agency's Diversion Control Division, led by Deputy Assistant Administrator Frank Sapienza, directly oversees cannabinoid scheduling. DEA's position reflects institutional concern about the proliferation of unregulated psychoactive substances and the agency's interpretation that the 2018 Farm Bill did not legalize synthetic cannabinoids.

Hometown Hero and Binoid (Plaintiff Companies)

Texas-based Hometown Hero, founded in 2015 by military veterans, became one of the largest HHC product manufacturers with estimated 2025 revenues of $47 million. The company filed suit in the U.S. District Court for the Western District of Texas on May 29, 2026, arguing that DEA's rule violated the Administrative Procedure Act by bypassing notice-and-comment requirements and exceeded the agency's statutory authority under the Farm Bill. California-based Binoid, established in 2018, filed a parallel lawsuit in the U.S. District Court for the Central District of California on June 3, 2026. Binoid's complaint emphasized that the company invested $8.3 million in HHC production equipment and inventory based on the Farm Bill's hemp definition. Both companies retained Paul Armentano, deputy director of the National Organization for the Reform of Marijuana Laws (NORML), as an expert witness.

U.S. Hemp Roundtable

The U.S. Hemp Roundtable, a coalition of hemp industry stakeholders, filed an amicus brief supporting the plaintiff companies on June 18, 2026. The organization argued that DEA's interpretation threatens the viability of the entire hemp industry by creating uncertainty about which hemp derivatives qualify as legal. General Counsel Jonathan Miller stated that the rule "eviscerates the Farm Bill's clear intent to legalize hemp and all its derivatives."

Food and Drug Administration

FDA has maintained a separate regulatory posture, focusing on HHC's status as an unapproved food additive and drug rather than its controlled substance classification. In March 2025, FDA issued warning letters to 14 companies marketing HHC products, citing violations of the Federal Food, Drug, and Cosmetic Act. The agency has not taken a public position on DEA's scheduling determination but coordinated with DEA through an interagency working group established in 2024.

State Attorneys General

Attorneys general from Arkansas, Kentucky, and Montana filed a joint amicus brief supporting DEA's rule on June 20, 2026. The brief argued that HHC products created public health risks in their states and that federal prohibition was necessary to support state-level enforcement. In contrast, attorneys general from Colorado, Oregon, and Michigan filed a separate brief arguing that DEA's rule disrupted established state regulatory frameworks and exceeded federal authority.

Legal and Regulatory Framework

The HHC dispute turns on the interaction between the Controlled Substances Act's scheduling provisions, the 2018 Farm Bill's hemp exemption, and the Administrative Procedure Act's rulemaking requirements. The Controlled Substances Act, enacted in 1970 as Title II of the Comprehensive Drug Abuse Prevention and Control Act, establishes five schedules of controlled substances under 21 U.S.C. § 812. Schedule I includes substances with high potential for abuse, no currently accepted medical use, and lack of accepted safety for use under medical supervision. The statute lists "tetrahydrocannabinols" in Schedule I at 21 U.S.C. § 812(c), Schedule I(c)(17). DEA's implementing regulations at 21 CFR § 1308.11(d)(31) define "tetrahydrocannabinols" to include "synthetic equivalents of the substances contained in the plant, or in the resinous extractives of Cannabis." This regulatory language, promulgated in 1993, predates the 2018 Farm Bill by 25 years. The 2018 Farm Bill amended the Controlled Substances Act by adding a new section, 21 U.S.C. § 802(16)(B), which excludes "hemp" from the definition of "marihuana." The statute defines hemp at 7 U.S.C. § 1639o(1) to include "all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers" of Cannabis sativa L. plants containing no more than 0.3 percent delta-9-THC. The central legal question is whether HHC qualifies as a "derivative" or "cannabinoid" of hemp under the Farm Bill's definition. Industry plaintiffs argue that because HHC is produced from hemp-derived CBD through hydrogenation, it constitutes a hemp derivative protected by the statutory exemption. They cite the Farm Bill's explicit inclusion of "isomers" and "derivatives" as evidence of congressional intent to legalize chemically modified hemp compounds. DEA counters that the term "derivative" refers to compounds directly extractable from the hemp plant, not substances requiring chemical synthesis. The agency argues that HHC produced through hydrogenation is a "synthetic equivalent" of tetrahydrocannabinol under 21 CFR § 1308.11(d)(31) and therefore remains a Schedule I controlled substance. DEA's position relies on the principle that the Farm Bill did not repeal the Controlled Substances Act's prohibition on synthetic cannabinoids; it merely created an exemption for naturally occurring hemp compounds. The Administrative Procedure Act, codified at 5 U.S.C. § 551 et seq., requires federal agencies to follow notice-and-comment procedures for "substantive rules" under 5 U.S.C. § 553. This process includes publishing a notice of proposed rulemaking in the Federal Register, allowing public comment for at least 30 days, and publishing a final rule that responds to significant comments. DEA issued its May 2026 HHC rule without prior notice or comment period, claiming exemption under 5 U.S.C. § 553(b)(3)(B), which allows agencies to bypass notice-and-comment for "interpretive rules" that clarify existing law rather than creating new obligations. Plaintiff companies argue that DEA's rule is a substantive rule requiring notice-and-comment because it changes the legal status of a commercially available product and creates new criminal liability. They cite the Supreme Court's decision in Perez v. Mortgage Bankers Association, 575 U.S. 92 (2015), which held that agencies must use notice-and-comment procedures when altering the legal landscape in ways that affect private parties. The Controlled Substances Act also requires DEA to make specific findings before scheduling a substance. Under 21 U.S.C. § 811(c), the agency must consider eight factors including the substance's actual or relative potential for abuse, scientific evidence of its pharmacological effect, the state of current scientific knowledge, and the risk to public health. Plaintiffs argue that DEA's rule made no such findings for HHC specifically, instead relying on general statements about synthetic cannabinoids. A separate legal question involves the "controlled substance analogue" provision at 21 U.S.C. § 813, which allows prosecution of substances "substantially similar" to Schedule I or II drugs when intended for human consumption. DEA has suggested that even if HHC is not explicitly scheduled, it qualifies as an analogue of delta-9-THC. However, the analogue statute applies only to substances intended for human consumption, and industry defendants argue that their products are sold as "not for human consumption" in compliance with FDA regulations.

State-by-State Breakdown

State responses to HHC range from explicit regulation to outright prohibition, creating a patchwork of conflicting legal frameworks that complicate federal enforcement.

Colorado

Colorado regulates HHC under its hemp-derived cannabinoid framework established in 2022. The Marijuana Enforcement Division requires HHC products to contain no more than 10 milligrams of total active cannabinoids per serving for edibles and limits total package size to 100 milligrams. Manufacturers must register with the state, conduct third-party laboratory testing for potency and contaminants, and use child-resistant packaging. Retail sales are restricted to individuals 21 and older. As of June 2026, Colorado had licensed 347 HHC product manufacturers. The state has not announced plans to enforce DEA's federal prohibition, creating a conflict between state-legal commerce and federal illegality.

Oregon

Oregon incorporated HHC into its existing hemp program on January 1, 2023, under Oregon Revised Statutes § 475C.770. The Oregon Liquor and Cannabis Commission requires HHC products to meet the same testing standards as marijuana products, including analysis for pesticides, heavy metals, mycotoxins, and residual solvents. Products must display a universal symbol and carry warnings about psychoactive effects. Retailers must hold hemp endorsements on their business licenses. Oregon's framework treats HHC as a regulated but legal product, with approximately 280 licensed retailers as of mid-2026.

Michigan

Michigan enacted comprehensive hemp-derived cannabinoid legislation in November 2024 through Public Act 220. The law defines "industrial hemp cannabinoid" to include HHC and establishes a regulatory system administered by the Department of Agriculture and Rural Development. Products must contain less than 10 milligrams of HHC per serving and display batch numbers linked to certificates of analysis. Michigan requires all HHC products to be manufactured in licensed facilities subject to annual inspections. The state issued 412 industrial hemp processor licenses by June 2026, many specifically for HHC production.

Texas

Texas has not enacted HHC-specific legislation, leaving the compound in legal limbo. The Texas Department of State Health Services regulates hemp under the Texas Hemp Program established pursuant to the 2018 Farm Bill, but has issued no guidance on semi-synthetic cannabinoids. This ambiguity allowed Texas to become the largest HHC market by volume, with an estimated $340 million in retail sales in 2025. DEA's May 2026 rule creates immediate enforcement risk for Texas businesses, as state law enforcement could now pursue charges under the Texas Controlled Substances Act, which incorporates federal scheduling by reference.

Florida

Florida's regulatory approach mirrors Texas, with no HHC-specific legislation but substantial market activity. The state's hemp program, administered by the Department of Agriculture and Consumer Services, focuses on agricultural production rather than finished products. Florida's retail HHC market reached approximately $290 million in 2025. The state's attorney general has not issued an opinion on HHC's legality under state law, but local prosecutors could now rely on DEA's scheduling determination to pursue state-level charges.

Arkansas

Arkansas banned HHC effective August 1, 2023, through emergency rules that classified the compound as a Schedule I controlled substance under Arkansas Code § 5-64-214. The Alcoholic Beverage Control Division cited public health concerns and lack of regulatory oversight. Possession of HHC products in Arkansas carries penalties identical to marijuana possession: up to one year imprisonment and a $2,500 fine for first-time offenders. The state has prosecuted approximately 40 HHC-related cases since the ban took effect.

Kentucky

Kentucky prohibited HHC on January 15, 2024, through administrative action by the Cabinet for Health and Family Services. The state added HHC to its Schedule I controlled substance list under Kentucky Revised Statutes § 218A.090. Kentucky's ban followed reports of HHC product sales to minors at gas stations and convenience stores. The state provides no exception for medical use or possession of products purchased before the ban.

Montana

Montana enacted House Bill 652 in April 2024, explicitly prohibiting "synthetically derived cannabinoids" including HHC, THC-O, and THCP. The law, codified at Montana Code Annotated § 50-32-101, defines synthetic cannabinoids as "any cannabinoid produced through chemical synthesis, isomerization, or other artificial process." Montana's statute includes a scienter requirement, meaning prosecutors must prove defendants knew the substance was synthetically derived. The law imposes civil penalties of up to $5,000 per violation for retailers and criminal penalties for manufacturers.

California

California has not banned HHC but subjects it to regulation under Assembly Bill 45, enacted in October 2023. The law requires hemp-derived cannabinoid products to be manufactured in facilities licensed by the Department of Cannabis Control and tested by state-licensed laboratories. Products must contain less than 0.3 percent delta-9-THC and display warnings about psychoactive effects. California prohibits sales to individuals under 21 and bans HHC products from being sold within 600 feet of schools. As of June 2026, California had issued 523 hemp product manufacturing licenses.

New York

New York regulates HHC under its Cannabis Law Article 4, which governs "cannabinoid hemp" products. The Office of Cannabis Management requires manufacturers to register with the state and submit products for testing. New York limits HHC edibles to 10 milligrams per serving and 100 milligrams per package. The state prohibits marketing HHC products with health claims or in packaging that appeals to children. New York's framework, established in November 2022, treats HHC as a legal but regulated product, with approximately 890 registered retailers as of mid-2026.

Market and Business Implications

DEA's HHC prohibition threatens to eliminate a $1.8 billion market segment and creates cascading financial consequences for hemp businesses, investors, and ancillary service providers. The immediate impact falls on manufacturers holding HHC inventory. Industry estimates suggest that hemp businesses collectively held $180 million to $240 million in HHC raw materials and finished products as of May 2026. DEA's rule provides no grace period for inventory disposal, creating potential asset forfeiture risk. Businesses cannot legally sell existing stock, cannot return products to suppliers without implicating them in controlled substance distribution, and face criminal liability for possession. Multi-state operators face particularly acute challenges. Hometown Hero reported that HHC products represented 38 percent of its total revenue in 2025. The company's June 2026 financial disclosure revealed $6.2 million in HHC inventory that became unsaleable overnight. Binoid estimated losses of $4.7 million in inventory and $8.3 million in specialized production equipment usable only for HHC synthesis. Smaller operators face bankruptcy risk; at least 17 hemp companies filed for Chapter 11 protection in June 2026, citing HHC-related losses. Upstream suppliers face parallel disruption. Chemical supply companies that sold hydrogenation catalysts and reagents specifically for HHC production—including Sigma-Aldrich, Fisher Scientific, and specialized hemp chemistry suppliers—lost a significant customer base. Laboratory testing facilities that invested in HHC-specific analytical methods face stranded capital costs. The rule's impact extends to adjacent cannabinoid markets. Delta-8-THC, which represents approximately $2.9 billion in annual sales, faces renewed legal uncertainty. While DEA's May 2026 rule addressed HHC specifically, the agency's reasoning—that synthetic production pathways trigger controlled substance classification—applies equally to delta-8-THC, which is typically produced through chemical isomerization of CBD. Industry analysts predict that DEA will issue similar determinations for delta-10-THC, THC-O-acetate, and THCP, potentially eliminating the entire semi-synthetic cannabinoid market worth an estimated $6.2 billion annually. Capital markets have responded negatively. Publicly traded hemp companies saw significant stock price declines following the May 2026 rule. Curaleaf Holdings, which acquired a hemp-derived cannabinoid business in 2024, saw its stock price decline 14 percent in the week following DEA's announcement. Private equity firms that invested in hemp businesses based on semi-synthetic cannabinoid revenue projections face impaired asset values. The rule creates strategic advantages for state-licensed cannabis operators. Multi-state operators including Trulieve, Green Thumb Industries, and Cresco Labs compete with hemp businesses for consumer spending on psychoactive cannabinoids. Eliminating legal HHC products channels consumer demand toward state-regulated marijuana markets, potentially increasing MSO revenues. Analysts at Cowen & Company estimated that DEA's HHC prohibition could shift $800 million to $1.2 billion in annual consumer spending from hemp retailers to state-licensed dispensaries. Banking and payment processing complications intensify. Financial institutions already reluctant to serve hemp businesses due to federal illegality concerns now face clear controlled substance distribution risks when processing HHC transactions. Several major payment processors, including Square and Stripe, issued guidance in June 2026 prohibiting HHC-related transactions. This forces remaining hemp businesses toward cash-only operations, increasing security risks and operational costs. Insurance implications are immediate. Product liability insurers have begun rescinding coverage for HHC products, citing the controlled substance classification. At least three major insurers—Cannasure, Cannected, and Hiscox—issued non-renewal notices to hemp businesses in June 2026. This leaves manufacturers and retailers exposed to uninsured liability for products already in distribution channels. Tax treatment adds another layer of complexity. Hemp businesses that sold HHC products may face retroactive application of Internal Revenue Code § 280E, which prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. If IRS determines that HHC was always a controlled substance, affected businesses could face tax assessments for prior years when they claimed deductions for rent, salaries, and other operating expenses related to HHC sales. Industry tax attorneys estimate potential retroactive tax liability in the range of $400 million to $600 million across the sector.

What Experts Say

Legal scholars, industry advocates, and public health experts offer sharply divergent assessments of DEA's HHC prohibition, reflecting broader disagreements about cannabis policy and administrative law. Paul Armentano, deputy director of NORML and an expert witness for plaintiff companies, characterized DEA's rule as "an unlawful end-run around both the Administrative Procedure Act and congressional intent in the Farm Bill." In a June 2026 declaration filed in the Hometown Hero litigation, Armentano argued that Congress explicitly legalized hemp derivatives in 2018 and that DEA lacks authority to re-prohibit compounds through interpretive rules. He noted that the Farm Bill's legislative history includes Senate floor statements by Majority Leader Mitch McConnell emphasizing that the statute legalized "all" hemp derivatives. Shane Pennington, a cannabis attorney at Vicente LLP who represents hemp industry clients, told Hemp Industry Daily that DEA's position "ignores basic chemistry and statutory construction." According to Pennington, the Farm Bill's inclusion of "isomers" and "derivatives" in the hemp definition clearly encompasses chemically modified compounds. He argued that DEA's distinction between "natural" and "synthetic" derivatives appears nowhere in the statutory text. In contrast, Robert Mikos, a law professor at Vanderbilt University and cannabis law expert, suggested that DEA's interpretation has statutory support. In a June 2026 law review article, Mikos wrote that the Controlled Substances Act's prohibition on "synthetic equivalents" of tetrahydrocannabinols predates the Farm Bill and was not explicitly repealed. He argued that Congress could have excluded synthetic cannabinoids from the Controlled Substances Act if it intended to legalize them, but chose not to do so. Mikos concluded that the legal question is "closer than industry advocates acknowledge." From a public health perspective, Dr. Nora Volkow, director of the National Institute on Drug Abuse, testified before Congress in March 2026 that semi-synthetic cannabinoids pose "significant and understudied health risks." According to Dr. Volkow, HHC products lack standardized dosing, contain variable levels of active compounds, and have not undergone clinical safety testing. She noted that NIDA-funded research documented cases of HHC-related adverse events including seizures, psychotic episodes, and cannabinoid hyperemesis syndrome. Dr. Volkow stopped short of endorsing DEA's scheduling approach but emphasized the need for regulatory oversight. Dr. Peter Grinspoon, a physician at Massachusetts General Hospital and cannabis policy advocate, offered a different public health perspective. In a June 2026 op-ed in STAT News, Dr. Grinspoon argued that prohibition-based approaches to cannabinoid regulation have failed historically and that DEA's HHC ban will drive consumers toward unregulated black markets. He advocated for FDA-led regulation focused on product safety, labeling, and age restrictions rather than criminal prohibition. Jonathan Miller, general counsel of the U.S. Hemp Roundtable, described DEA's rule as "an existential threat to the hemp industry" in testimony before the House Agriculture Committee on June 15, 2026. Miller argued that the rule's logic would prohibit common hemp processing techniques including winterization, distillation, and isomerization, effectively limiting legal hemp products to raw plant material. He called on Congress to clarify the Farm Bill's scope through corrective legislation. Administrative law scholars have focused on the procedural dimensions. Professor Nicholas Bagley of the University of Michigan Law School wrote in a June 2026 blog post that DEA's claim to interpretive rule exemption is "highly questionable." According to Bagley, the rule imposes new legal obligations on private parties and cannot reasonably be characterized as mere clarification of existing law. He predicted that courts would likely find an Administrative Procedure Act violation. Professor Cass Sunstein of Harvard Law School, a former administrator of the Office of Information and Regulatory Affairs, took a more nuanced view. In a June 2026 article, Sunstein acknowledged that DEA's rule raises procedural concerns but noted that agencies have broad discretion to issue interpretive rules when clarifying ambiguous statutory terms. He suggested that the outcome would depend on whether courts view the Farm Bill's hemp definition as clearly encompassing synthetic derivatives or as ambiguous on that point.

What's Next

The HHC controversy will unfold through parallel litigation, potential congressional action, and DEA's broader synthetic cannabinoid enforcement strategy over the next 12 to 24 months. The immediate timeline centers on the two federal lawsuits. The Hometown Hero case in the Western District of Texas and the Binoid case in the Central District of California both seek preliminary injunctions blocking enforcement of DEA's May 2026 rule.